Evidence Synthesis in Harm Assessment of Medicines Using the Example of Rosiglitazone and Myocardial Infarction

The current system of harm assessment of medicines has been criticized for relying on intuitive expert judgment. There is a call for more quantitative approaches and transparency in decision-making. Illustrated with the case of cardiovascular safety concerns for rosiglitazone, we aimed to explore a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rietbergen, Charlotte, Stefansdottir, Gudrun, Leufkens, Hubert G., Knol, Mirjam J., De Bruin, Marie L., Klugkist, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827152/
https://www.ncbi.nlm.nih.gov/pubmed/29520360
http://dx.doi.org/10.3389/fmed.2017.00228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827152/
https://www.ncbi.nlm.nih.gov/pubmed/29520360
http://dx.doi.org/10.3389/fmed.2017.00228

Ejemplares similares